Search

Find exactly what you’re looking for.
Search

Service
Showing 61-80 of 181 results

Since Elon Musk announced his decision to remove the iconic bird logo and adopt "X", as Twitter's new logo (the "X Logo"), the rebranding decision has been the talk of the town. The rollout has prompted a barrage of reactions and has many questioning whether the change will attract legal hurdles...

A recent opinion from the 3rd Circuit U.S. Court of Appeals confirmed what should be settled law: deathbed gifts made by personal check delivered before death but deposited after death remain part of the donor’s taxable estate and thus subject to estate tax. A lot of taxes, legal fees, and headache...

Saul Ewing LLP, a full-service national law firm, today announced that the firm was recognized as Band 1 for Private Wealth Law in Maryland in Chambers High Net Worth 2023. Additionally, Jeff Glaser, chair of the firm's Personal Wealth, Estates & Trusts Practice, was ranked as a Band 1 attorney...

A recently filed class action lawsuit raises more legal challenges to providers of generative artificial intelligence (AI) tools that are used to create content. The suit cautions that a doomsday scenario is approaching and alleges a host of privacy and other violations occurring along the way. What...

NEW YORK, NY, (June 27, 2023) – In joining Saul Ewing as a new partner, Peri Berger will represent clients facing complex commercial disputes involving breach of contract, fraud, business ownership and control, intellectual property, trade secrets and other threats related to their operations in...

On June 8, 2023, the Supreme Court issued a unanimous decision in Jack Daniel’s Properties, Inc. v. VIP Products LLC, 599 U.S. ---, 2023 WL 3872519, reversing VIP Products’ victory in a trademark case against Jack Daniel’s, and remanding to the Arizona District Court for further proceedings. What...

​On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...

For More Information
Contact us